Figure 1.

The viability of BV-2 cells. (a) The viability of BV-2 cells exposed to zileuton. Differences in the viability of BV-2 cells exposed to different concentrations of zileuton were evaluated via the cell count kit-8 (CCK-8) assay. The x-axis represents the control group and vehicle, as well as different concentrations (5, 10, 15, and 20 μΜ) of zileuton; the y-axis represents the cell viability expressed as a percentage relative to the control group. Using the different concentrations of zileuton for 24 h did not inhibit the viability of BV-2 cells (n = 5). (b) The viability of haemolysate-exposed BV-2 cells treated with different concentrations of zileuton. Differences in the viability of haemolysate-exposed BV-2 cells treated with different concentrations of zileuton were evaluated via the CCK-8 assay. The x-axis represents the control group and vehicle, as well as different concentrations (5, 10, 15, and 20 μΜ) of zileuton; the y-axis represents the cell viability expressed as a percentage relative to the control group. The haemolysate-exposed BV-2 cells treated with the vehicle or 5, 10, and 15 μM of zileuton showed significantly higher viability than BV-2 cells in the control group (p < 0.001). The viability of BV-2 cells in the haemolysate + 20 μM zileuton group was significantly lower than that of cells in the haemolysate group (p < 0.001). There was no significant difference in the viability of BV-2 cells between the haemolysate + 20 μM zileuton group and the control group. The experimental results revealed that 20 μM of zileuton can inhibit the haemolysate-induced over-proliferation of BV-2 cells (*** p < 0.001 compared with control; ^### p < 0.001 compared with haemolysate group, n = 5).